Beam Therapeutics (BEAM) vs CRISPR Therapeutics (CRSP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Beam Therapeutics (BEAM) has outperformed CRISPR Therapeutics (CRSP) over the past year, losing 5.9% versus a loss of 22.2%. Over five years, CRSP leads with a -50.4% price change compared with -73.4% for BEAM. CRISPR Therapeutics is the larger company by market cap ($3.79 billion vs $2.16 billion), about 1.8 times the size, while Beam Therapeutics is growing revenue faster (+120.0% vs -90.6%).
Beam Therapeutics converts more of its revenue into profit, with a net margin of -57.2% versus -16569.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BEAM | CRSP |
|---|---|---|
| Share price | $20.90 | $39.10 |
| Market cap | $2.16B | $3.79B |
| 1-day change | -0.19% | +0.44% |
| YTD return | -24.60% | -25.44% |
| 1-year return | -5.90% | -22.16% |
| 5-year return | -73.44% | -50.37% |
| EPS (TTM) | $-0.87 | $-4.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $139.74M | $3.51M |
| Revenue growth (YoY) | +120.01% | -90.59% |
| Net income (latest FY) | $-79.99M | $-581.60M |
| Operating margin | -274.57% | -18933.65% |
| Net margin | -57.24% | -16569.77% |
| 52-week high | $38.26 | $63.45 |
| 52-week low | $20.44 | $38.15 |
| Distance from 52-week high | -45.37% | -38.38% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +138.52% | +118.47% |
| Average volume | 2.04M | 1.74M |
| Shares outstanding | 103.50M | 97.00M |
| Employees | 557 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BEAM has outperformed CRSP by 16.3 percentage points over the past year.
- Beam Therapeutics is more profitable, keeping -57.2 cents of every revenue dollar as net income versus -16569.8 cents for CRISPR Therapeutics.
- Beam Therapeutics grew revenue faster in its latest fiscal year (+120.01% vs -90.59%).
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 557 employees
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
BEAM vs CRSP FAQ
Which is bigger, Beam Therapeutics or CRISPR Therapeutics?
CRISPR Therapeutics (CRSP) is larger, with a market capitalization of $3.79B compared with $2.16B for Beam Therapeutics (BEAM).
Which stock has performed better over the past year, BEAM or CRSP?
BEAM returned -5.90% over the past 12 months, compared with -22.16% for CRSP (price return, excluding dividends). Past performance does not predict future results.
Are Beam Therapeutics and CRISPR Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.